Testosterone replacement therapy risks: The ones men miss until a lab test catches them

Testosterone replacement therapy risks are manageable for many men with confirmed hypogonadism, but they are not trivial and they require structured monitoring. The most common problems build slowly, so the men who do best are the ones who treat TRT like a medical program, not a quick upgrade.

Key takeaways

• According to the Endocrine Society, clinicians should intervene if hematocrit rises above 54% on TRT because thicker blood can raise clot risk.^[1]
• Exogenous testosterone can suppress sperm production to near zero during treatment, and recovery often takes 6 to 12 months after stopping and is not guaranteed.^[5]
• Guidelines diagnose testosterone deficiency when symptoms match repeat low early morning labs, often using total testosterone below 300 ng/dL on two separate tests, with free testosterone most helpful when SHBG is abnormal.^[1]
• Large randomized data found testosterone was noninferior to placebo for major adverse cardiovascular events in appropriately selected men, but some events like atrial fibrillation and pulmonary embolism may occur more often and warrant monitoring.^[4]
• Plan baseline labs, repeat testing at 3 to 6 months, and at least yearly follow up once stable. “Set it and forget it” is where testosterone replacement therapy risks show up.^[1],[2]

Why TRT risk is a profile, not a single yes or no

Testosterone replacement therapy risks depend on who is taking testosterone, why they are taking it, and how closely the plan is monitored. TRT is prescription testosterone designed to raise levels into a healthier range. In men with true testosterone deficiency, it can improve sexual symptoms, energy, and body composition, but the same hormone signals can also raise red blood cells, worsen urinary symptoms in men with prostate enlargement, and suppress fertility.^[1]

Hypogonadism is persistently low testosterone plus compatible symptoms. SHBG is sex hormone binding globulin, a carrier protein that changes how much testosterone is available to tissues. According to the Endocrine Society guideline, the diagnosis requires symptoms plus consistently low early morning testosterone on at least two separate tests, often using total testosterone below 300 ng/dL as a practical cutoff, and using free testosterone when SHBG is abnormal.^[1]

When men meet those criteria and are carefully followed, the biggest cardiovascular fears look less dramatic in modern randomized trials. MACE is major adverse cardiovascular events, usually heart attack, stroke, or cardiovascular death. According to the 2023 NEJM TRAVERSE trial in men with hypogonadism and elevated baseline cardiovascular risk, testosterone was noninferior to placebo for MACE, but some adverse events such as atrial fibrillation and pulmonary embolism occurred more often in the testosterone group.^[4] A 2022 individual patient data meta analysis also found no evidence of increased short to medium term MACE overall in randomized trials.^[3]

How TRT creates side effects in the male body

It can raise hematocrit and thicken blood

One of the most important testosterone replacement therapy risks is erythrocytosis. Erythrocytosis is an abnormally high red blood cell level. Hematocrit is the percentage of your blood made up of red cells. Testosterone can stimulate red blood cell production and push hematocrit above about 52% to 54%, especially with higher dose regimens and, in some men, injectable formulations that create higher peaks.^[1],[6]

Organization guidance provides a clear “action line.” According to the Endocrine Society, clinicians should intervene if hematocrit exceeds 54% during TRT. That can mean lowering the dose, pausing therapy, or evaluating other contributors such as smoking or untreated sleep apnea.^[1]

It affects cardiovascular load without a simple “safe or unsafe” label

TRT influences vascular tone and salt and water balance, and it can also raise red blood cells, so the net cardiovascular effect depends on baseline risk and dosing strategy.^[1] Venous thromboembolism is a blood clot in a vein. Pulmonary embolism is a clot that travels to the lungs. Atrial fibrillation is a common irregular heartbeat that can raise stroke risk.

According to the 2023 NEJM TRAVERSE trial, testosterone was noninferior to placebo for MACE in monitored men with hypogonadism and elevated cardiovascular risk, but atrial fibrillation and pulmonary embolism were more frequent in the testosterone group, which supports ongoing surveillance rather than complacency.^[4] According to the Endocrine Society guideline, TRT is generally avoided or delayed in men with recent heart attack or stroke or poorly controlled heart failure because the benefit to risk balance is less favorable.^[1]

It can worsen urinary symptoms and complicate prostate monitoring

Testosterone does not automatically “cause” prostate cancer, but it does stimulate androgen responsive prostate tissue, which matters for symptom control and screening. BPH is benign prostatic hyperplasia, noncancerous prostate growth that can narrow the urine channel. LUTS are lower urinary tract symptoms such as weak stream and nighttime urination. PSA is prostate specific antigen, a blood marker used to screen for and monitor prostate cancer.

According to American Urological Association guidance, TRT is avoided in men with active prostate cancer, and PSA monitoring is part of safe TRT because PSA can rise on therapy and can flag when more evaluation is needed.^[2] Research summarized in urology guidance also notes TRT can increase prostate size somewhat and may worsen LUTS in men who already have significant BPH.^[2]

It can shut down sperm production through brain feedback

Fertility suppression is one of the most misunderstood testosterone replacement therapy risks. LH is luteinizing hormone, a brain signal that tells the testes to make testosterone. FSH is follicle stimulating hormone, a brain signal that supports sperm production. When a man takes external testosterone, the brain senses “enough” and turns down LH and FSH, which can shrink testicular output and drop sperm counts to very low levels during treatment.^[5]

According to research on exogenous testosterone as a preventable cause of male infertility, sperm recovery often takes 6 to 12 months after stopping TRT, and it is not guaranteed for every man, especially with prolonged use or older age.^[5]

It shifts hormone conversion, skin, mood, and sleep

Testosterone can convert to DHT and estradiol. DHT is dihydrotestosterone, a stronger androgen in skin and hair follicles. Estradiol is an estrogen that men also make in smaller amounts, and it helps regulate bone and other tissues. These shifts can contribute to oily skin, acne, hair loss in genetically prone men, fluid retention, and sometimes gynecomastia, which is benign breast tissue growth that can be tender.^[1]

Sleep is another watch item. Obstructive sleep apnea is repeated breathing pauses during sleep due to upper airway collapse. Research published in The Journal of Clinical Endocrinology and Metabolism found short term high dose testosterone worsened sleep and breathing in older men, supporting screening for loud snoring and unrefreshing sleep, especially in men with higher body weight.

Conditions that raise testosterone replacement therapy risks

Some situations make testosterone replacement therapy risks more likely or more consequential. This is where a clinician should slow down, confirm the indication, and build a plan that fits your starting health.

• High baseline hematocrit or prior polycythemia: Polycythemia means too many red blood cells. TRT can push hematocrit above about 52% to 54%, raising blood viscosity and potentially clot risk, particularly with higher doses and some injection patterns.^[1],[6]
• Known cardiovascular disease or prior clot: Large randomized data did not show a major increase in MACE in appropriately selected men, but TRAVERSE reported more atrial fibrillation and pulmonary embolism in the testosterone group, so men with baseline rhythm or clot risk need closer monitoring and conservative dosing.^[4]
• Recent heart attack or stroke, or poorly controlled heart failure: According to the Endocrine Society, TRT is typically avoided or delayed in these settings because risk may outweigh benefit until the condition is stable.^[1]
• Symptomatic BPH: If you already have weak stream, hesitancy, or frequent nighttime urination, TRT may worsen symptoms. Symptom scoring and treatment adjustments should happen before starting.^[2]
• Active prostate cancer or concerning prostate markers: According to the AUA, TRT is avoided in active prostate cancer and PSA monitoring is part of safe care.^[2]
• Near term fertility goals: Exogenous testosterone can function like contraception by suppressing LH and FSH, so it is generally avoided when conception is a priority.^[5]
• Sleep apnea symptoms: If loud snoring, gasping, and daytime sleepiness are present, untreated sleep apnea can amplify cardiovascular and fatigue risks, and testosterone may worsen breathing in some men.

Limitations note: Safety conclusions are strongest for men who resemble those studied in randomized trials, meaning confirmed hypogonadism, appropriate indications, and structured monitoring. Longer term outcomes and results in higher risk groups, such as men with very recent major cardiovascular events, are still being clarified.^[3],[4]

Symptoms and signals men should not ignore

Most testosterone replacement therapy risks develop gradually. That is why men often miss them until a lab result changes or a partner notices snoring, mood, or swelling. Use this as a practical “check engine” list.

• Possible heart or clot warning signs: chest pressure with activity, sudden shortness of breath, swelling in one leg, pounding or irregular heartbeat, sudden weakness on one side, new trouble speaking. Seek urgent care for these symptoms.^[4]
• Possible high hematocrit symptoms: frequent headaches, flushed face, nosebleeds, blurred vision, feeling unusually sluggish or “thick headed.” Ask your clinician for a complete blood count.^[1]
• Possible prostate or urinary worsening: weaker urine stream, starting and stopping, needing to urinate often especially at night, burning with urination, blood in urine or semen. Ask about LUTS scoring and PSA follow up when appropriate.^[2]
• Possible fertility suppression: difficulty conceiving after months of trying, shrinking testicles, lower ejaculation volume. If kids are a goal, do not assume TRT is neutral for fertility.^[5]
• Possible sleep apnea worsening: loud snoring reported by others, gasping or choking during sleep, waking unrefreshed, morning headaches, severe daytime sleepiness. The fix may be sleep evaluation, not more testosterone.
• Possible mood and dosing instability: new irritability, feeling “amped up,” trouble falling asleep, mood swings that feel out of character. Peaks and troughs may be part of the story, especially with some injection schedules.^[1]
• Possible fluid and skin effects: sudden acne flare on back or shoulders, rapid weight gain over a few days, ankle or hand swelling, breast tenderness. These can relate to hormone conversion and fluid retention.^[1]

If symptoms are mild but persistent, the safest first step is usually not to self adjust your dose. Contact the prescribing clinician to review timing and order targeted labs, especially a complete blood count for hematocrit and hemoglobin, a testosterone level timed to your regimen, and PSA when appropriate.^[1],[2]

What to do about it

Lowering testosterone replacement therapy risks is mostly about doing the basics well: confirm the diagnosis, pick the right therapy for your goals, and monitor like you would monitor blood pressure or cholesterol.

1. Confirm you actually need treatment: According to the Endocrine Society, diagnose hypogonadism only when symptoms match repeat low early morning testosterone on two separate tests, with free testosterone interpreted using the lab’s reference range when SHBG is abnormal.^[1] Many clinicians use total testosterone around 300 ng/dL as a practical cutoff, but borderline results should trigger repeat testing and a search for common contributors to symptoms, including sleep apnea, obesity, depression, medication effects, and chronic illness.^[1],[2] Some clinics also use internal decision points such as total testosterone below 350 ng/dL or free testosterone below 100 pg/mL when symptoms persist, but these are not guideline cutoffs and they depend heavily on the assay (free testosterone by equilibrium dialysis vs calculated) and the laboratory’s reference range; diagnosis still requires symptoms plus consistently low morning testosterone measured with validated methods.
2. Match the therapy to your fertility goals and your labs: If you may want children, treat standard exogenous testosterone as a potential contraceptive, not a fertility aid, because it can suppress sperm production to near zero during therapy.^[5] If fertility preservation is important, discuss alternatives with a specialist; in some regions, clinicians may use medications intended to stimulate endogenous testosterone production (for example, selective estrogen receptor modulators such as clomiphene or enclomiphene, or gonadotropins such as hCG). Availability and regulatory approval vary by country, and some uses are off label; these options have contraindications (including a history of thromboembolism for some men), potential adverse effects (such as visual symptoms, mood changes, or elevated estradiol), and require monitoring of symptoms, testosterone/estradiol, blood counts, and semen parameters when conception is the goal. If TRT is still the right choice, discuss formulation. Gels and patches can provide steadier levels but require daily use and careful handling to prevent skin transfer to children or partners in your household. Injections are often cheaper but may create larger peaks and troughs and higher rates of elevated hematocrit in some men.^[6]
3. Monitor early and respond fast to drift: Organization guidelines recommend labs at baseline, again at 3 to 6 months, and at least yearly once stable, with clear action thresholds.^[1],[2] The key lab is a complete blood count. According to the Endocrine Society, intervene if hematocrit exceeds 54% by lowering dose, pausing therapy, or investigating contributors like smoking or sleep apnea.^[1] According to the AUA, monitor PSA and prostate symptoms using shared decision making based on baseline risk, since PSA can change on treatment and may prompt further evaluation.^[2] If sleep worsens, screen for obstructive sleep apnea, since testosterone can worsen breathing in some men and untreated apnea raises cardiometabolic risk on its own. The practical takeaway is to use a structured follow up process where lab timing, symptom review, and dose adjustments are part of the prescription, not an afterthought.

Myth vs fact

• Myth: “Testosterone replacement therapy risks always mean heart attacks.”
  Fact: A 2022 individual patient data meta analysis and the 2023 TRAVERSE trial did not show a major increase in MACE in appropriately selected, monitored men, but atrial fibrillation and pulmonary embolism can still occur and must be watched for.^[3],[4]
• Myth: “If my testosterone is low once, I should start TRT right away.”
  Fact: Endocrine Society guidance recommends symptoms plus two separate early morning low tests before diagnosing hypogonadism and treating.^[1]
• Myth: “TRT helps male fertility.”
  Fact: Exogenous testosterone suppresses LH and FSH and can drop sperm counts to near zero during treatment, with recovery often taking 6 to 12 months after stopping and not guaranteed for every man.^[5]
• Myth: “Once my dose is set, lab monitoring is optional.”
  Fact: Hematocrit, testosterone levels, and PSA can drift over time, and hematocrit above 54% is a widely used safety trigger that requires action.^[1],[2]
• Myth: “If I feel tired on TRT, I just need more testosterone.”
  Fact: Worsening snoring, morning headaches, and unrefreshing sleep can signal sleep apnea, which testosterone may aggravate in some men, so the fix may be sleep evaluation and treatment, not dose escalation.

Bottom line

The most commonly missed testosterone replacement therapy risks are the ones you often detect on labs before you feel them, especially rising hematocrit (erythrocytosis) and changes in prostate surveillance markers such as PSA.^[1],[2] If you start TRT for confirmed hypogonadism, plan baseline testing, repeat labs at 3 to 6 months, and at least annual monitoring thereafter, with faster follow up if values drift or symptoms change.^[1]

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2018;103:1715-1744. PMID: 29562364
2. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. The Journal of urology. 2018;200:423-432. PMID: 29601923
3. Hudson J, Cruickshank M, Quinton R, et al. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. The lancet. Healthy longevity. 2022;3:e381-e393. PMID: 35711614
4. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. The New England journal of medicine. 2023;389:107-117. PMID: 37326322
5. Crosnoe LE, Grober E, Ohl D, et al. Exogenous testosterone: a preventable cause of male infertility. Translational andrology and urology. 2013;2:106-13. PMID: 26813847
6. Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis Following Testosterone Therapy. Sexual medicine reviews. 2018;6:77-85. PMID: 28526632